A Phase 1 interventional study of SHR-7590 and Placebo in Moderate-to-severe Inflammatory Bowel Disease, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
…and 33 more changes, on the record history on ClinicalTrials.gov ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase I first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-7590 via subcutaneous or intravenous administration in Chinese healthy participants and patients with moderate-to-severe inflammatory bowel disease.
Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Part 1
Part 2:Participants with moderate to severe inflammatory bowel disease (ulcerative colitis and Crohn's disease)
Participants must meet all of the following criteria to be included in this study:
If the participant is currently receiving any of the following UC or CD treatments, they should receive a stable dose of medication within the specified time frame. The specific requirements are as follows:
Female participants with reproductive capacity or their male partners with reproductive capacity, starting from the date of signing the informed consent until the end of the safety follow-up period, have no plans for pregnancy, sperm donation, or egg donation, and voluntarily take effective contraceptive measures (including the partner, as detailed in Appendix 1). Female participants during the screening period and before the first administration must have a negative pregnancy test result and must be non-lactating.
---
Part of participants with moderate to severe ulcerative colitis:
Participants must meet all of the following criteria to enter this study:
Participants with active ulcerative colitis with a modified 9-point Mayo score of 4 to 9 and an endoscopic item score of 2 to 3, and with a bleeding item score of at least 1.
---
Part of participants with moderate to severe Crohn's disease:
Participants must meet all of the following criteria to enter this study:
Exclusion Criteria:
- Part 1
Part 2:
Participants with moderate to severe inflammatory bowel disease (ulcerative colitis and Crohn's disease) who have any of the following conditions are not eligible to participate in this study (common section):
1. Medical History or Comorbidities
1. Participants who have been diagnosed with ulcerative colitis or Crohn's disease and are on the initial treatment (without previous treatment).
2. During the screening endoscopy, participants have a history of gastrointestinal dysplasia (atypical hyperplasia)/cancer or atypical hyperplasia/cancer. Exclude complete low-grade dysplasia that has been completely removed.
3. Have evidence of pathogenic intestinal infection. 4. Currently or previously have:
Had any infection requiring antimicrobial treatment within 2 weeks before screening.
2. Prior Treatments and Clinical Studies 5. Participants who received azathioprine/6-mercaptopurine, methotrexate, thalidomide treatment within 2 weeks before baseline.
6. Participants who received cyclosporine, mycophenolate mofetil, tacrolimus or intravenous within 8 weeks before baseline.
7. Participants who received interferon treatment. 8. Participants who received rectal corticosteroid preparations or 5-ASA treatment within 2 weeks before baseline.
9. Participants who have participated in any clinical study of drugs (including investigational vaccines) or medical devices within 3 months before baseline or within 5 half-lives (whichever is longer).
3. Important Medical History or Underlying Diseases Affecting Safety
4. Laboratory Tests and Abnormalities
5. General Conditions
The investigator judges that there are situations that affect the safety and efficacy evaluation of the study drug.
---
Part of participants with severe ulcerative colitis:
Participants with any of the following conditions cannot be enrolled in this study:
6. UC-specific Exclusions
1. Participants with clinical manifestations diagnosed as undetermined colitis or suggesting Crohn's disease.
2. Participants with ulcerative colitis, limited to proctitis (distal ≤ 15 cm). 3. Participants showing clinical symptoms of ischemic colitis, fulminant colitis or toxic megacolon.
4. Participants who have previously undergone surgical treatment for ulcerative colitis or who may require surgical treatment during the study period.
Participants with moderate to severe Crohn's disease:
Any of the following conditions must be absent for a participant to be eligible for this study:
7. CD-specific Exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will receive SHR-7590 at dose level A. Subject will receive placebo at dose level A.
Drug: SHR-7590 · Drug: Placebo
Subject will receive SHR-7590 at dose level B. Subject will receive placebo at dose level B.
Drug: SHR-7590 · Drug: Placebo
Subject will receive SHR-7590 at dose level C. Subject will receive placebo at dose level C.
Drug: SHR-7590 · Drug: Placebo
Subject will receive SHR-7590 at dose level D. Subject will receive placebo at dose level D.
Drug: SHR-7590 · Drug: Placebo
Subject will receive SHR-7590 at dose level E. Subject will receive placebo at dose level E.
Drug: SHR-7590 · Drug: Placebo
Subjects with Ulcerative Colitis will receive SHR-7590 at dose level A
Drug: SHR-7590
Subjects with Ulcerative Colitis may receive SHR-7590 at dose level B(optional)
Drug: SHR-7590
Subjects with Crohn's Disease will receive SHR-7590 at dose level C
Drug: SHR-7590
Subjects with Crohn's Disease may receive SHR-7590 at dose level D (optional)
Drug: SHR-7590
SHR-7590
Placebo
Part1: Adverse events
Time frame: From ICF signing date to Day 281
Part1: Serious adverse events
Time frame: From ICF signing date to Day 281
Part2: Adverse events
Time frame: From ICF signing date to Day 393
Part2: Serious adverse events
Time frame: From ICF signing date to Day 393
Part2: Results of 12-lead electrocardiography
Time frame: From ICF signing date to Day 393
Part1:Maximum observed concentration of SHR-7590 (Cmax)
Time frame: From 0 hour date to Day 281
Part1: Time to maximum observed concentration (Tmax) of SHR-7590
Time frame: 0 hour to Day 281
Part1: Area under the drug-time curve from 0 to the last quantifiable time point (AUC0-last) of SHR-7590
Time frame: 0 hour to Day 281
Part1: Area under the drug-time curve from time 0 to infinity of SHR-7590(AUC0-inf)
Time frame: 0 hour to Day 281
Part1: Half-life (T1/2) of SHR-7590
Time frame: 0 hour to Day 281
Part1: Clearance (CL) of SHR-7590
Time frame: 0 hour to Day 281
Part1: Apparent clearance(CL/F)of SHR-7590
Time frame: 0 hour to Day 281
Part1: Volume of distribution (Vd)or apparent volume of distribution (Vd/F)of SHR-7590
Time frame: 0 hour to Day 281
Part2: Maximum observed concentration of SHR-7590 (Cmax)
Time frame: From 0 hour date to Day 393
Part2: Time to maximum observed concentration (Tmax) of SHR-7590
Time frame: 0 hour to Day 393
Part2: Area under the drug-time curve from 0 to the last quantifiable time point (AUC0-last) of SHR-7590
Time frame: 0 hour to Day 393
Part2: Area under the drug-time curve from time 0 to infinity of SHR-7590(AUC0-inf)
Time frame: 0 hour to Day 393
Part2: Half-life (T1/2) of SHR-7590
Time frame: 0 hour to Day 393
Part2: Clearance (CL) of SHR-7590
Time frame: 0 hour to Day 393
Part2: Apparent clearance(CL/F)of SHR-7590
Time frame: 0 hour to Day 393
Part2: Volume of distribution (Vd)or apparent volume of distribution (Vd/F)of SHR-7590
Time frame: 0 hour to Day 393
Part2: Immunogenicity of SHR-7590 in healthy participants and patients with moderate-to-severe ulcerative colitis.
Time frame: 0 hour to Day 393
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Mar 2028, 19 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jan 2027 → Mar 2028 and completion Dec 2027 → Apr 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
…and 33 more changes, on the record history on ClinicalTrials.gov ↗
…and 33 more changes, on the record history on ClinicalTrials.gov ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangdong Hengrui Pharmaceutical Co., Ltd →